Navigation Links
Dutch Biotech Company Pepscan Appoints New CEO
Date:12/2/2009

LELYSTAD, The Netherlands, December 2 /PRNewswire/ -- Pepscan Holding NV, the Netherlands based biotechnology company focusing on protein mimicking technology for the generation of immune therapeutics today announced that it has appointed Wim E.M. Mol, Ph.D. as new Chief Executive Officer.

Dr. Mol will be responsible for all of Pepscans corporate functions and the overall management and strategic direction of the company. He brings to Pepscan more than 20 years of management experience in the international pharmaceutical industry.

Dr. Mol was previously at Schering Plough where he was Vice-President responsible for the global scientific development and commercial strategy of a Phase III project in an alliance with a subsidiary of Merck-Serono. Dr. Mol commented, "I look forward to working with the highly professional and talented team at Pepscan. It is exciting to contribute to the creation of new therapeutic antibodies against currently intractable targets, using manmade mimics of the biologically relevant part of the target".

"Dr. Mol has tremendous experience that will be very valuable to Pepscan. He has held multiple executive level roles, including general management positions in the USA and other countries, and executive director positions in global marketing and alliance management. With his track record as a result-driven leader, I am confident that he will bring Pepscan to the next level as a leading company in the field of protein mimicry, fully exploiting its proprietary CLIPS(TM) technology", said Wim Jongen, Chairman of the Board.

Joost van Bree Ph.D., who has been fully supportive of the change in business focus towards CLIPS based technology has decided to step down as CEO and continue to work on the development of therapeutic vaccines. Mr. Jongen said, "Joost has been instrumental in broadening the company portfolio and creating the momentum for growth. His contribution has been enormous and in this new phase of the company, he will continue to focus on the successful development of the proprietary pipeline of the therapeutic vaccine portfolio".

Notes to the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the Netherlands. The company focuses on immunotherapy. It has developed a pipeline of therapeutic vaccine and antibody programs, of which the most advanced is in Phase II clinical testing. Pepscans proprietary CLIPS(TM) technology has been proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs. For more information visit http://www.pepscan.com.

About CLIPS(TM) technology

CLIPS(TM) (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains and hitherto have been used in antibody and vaccine programs to create superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).

SOURCE Pepscan Holding N.V.


'/>"/>
SOURCE Pepscan Holding N.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
2. Boost for Malaria Vaccine Development by Combining Strengths of Dutch and American Researchers
3. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
4. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
5. Cell Therapeutics Amends Modified Dutch Auction Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
6. Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market
7. Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its $118.9 Million Outstanding Convertible Notes
8. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
11. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):